SHIEFShield Therapeutics PLC

About Shield Therapeutics PLC (SHIEF)

Shield Therapeutics PLC (SHIEF) is a Drug Manufacturers - Specialty & Generic company headquartered in Gateshead Quays, ENG, United Kingdom whose shares trade over-the-counter on the OTCQB tier.

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield's lead product, Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland, Australia and Canada and has exclusive IP rights until the mid-2030s. The Group has launched Accrufer® in the US. Feraccru® is being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer®/Feraccru® in China, Hong Kong, Macau, and Taiwan, Korea Pharma Co., Ltd. in the Republic of Korea and with KYE Pharmaceuticals Inc in Canada.

Products and services

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield’s lead product, Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland, Australia and Canada and has exclusive IP rights until the mid-2030s. The Group has launched Accrufer® in the US. Feraccru® is being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer®/Feraccru® in China, Hong Kong, Macau, and Taiwan, Korea Pharma Co., Ltd. in the Republic of Korea and with KYE Pharmaceuticals Inc in Canada.

SHIEF key facts

Ticker symbol

SHIEF

Market tier

OTCQB

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Headquarters

Gateshead Quays, ENG, United Kingdom

Country of incorporation

GB

Year of incorporation

2008

Employees

75

Estimated market cap

$35.42M (as of May 14, 2025)

Shares outstanding

1,041,690,484

Reporting standard

International Reporting: LSE - London Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Semi-Annual Report (Jun 30, 2024)

Shield Therapeutics PLC leadership

• Santosh Shanbhag — CFO
• Lucy Huntington-Bailey — General Counsel
• Paul Spoors — Accountant
• Stephanie Hicks — Corp. Commun.

Explore more: Drug Manufacturers - Specialty & Generic stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with S